Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Table 1 Clinical data of 120 chronic hepatitis C virus (F0-F4) patients

	HCV patients with different fibrosis grade (n = 120)
	F0 (n = 30)	F1 (n = 30)	F2-3 (n = 30)	F4 (n = 30)
Age (yr)	38.4 ± 7.1	41.5 ± 8.7	43.5 ± 8.4	48.3 ± 9.3
Sex (female/male)	13/17	12/18	10/20	9/21
BMI (kg/m2)	25.5 ± 2.3	27.6 ± 3.4	28.7 ± 2.7	29.5 ± 2.7
ALT (U/L)	23.4 ±7.1	39.8 ± 23.7	51.1 ± 20.7	60.1 ± 20.3
AST (U/L)	22.4 ± 6.5	34.9 ± 20.9	48.9 ± 25.9	58.7 ± 18.6
ALP (U/L)	113.6 ± 32.8	122.5 ± 37.1	158.7 ± 47.7	153.8 ± 53.5
Total bilirubin (mg/dL)	0.53 ± 0.32	0.61 ± 0.23	0.96 ± 0.37	1.60 ± 0.65
Albumin (g/dL)	4.10 ± 0.33	4.00 ± 0.38	3.80 ± 0.45	3.50 ± 0.39
Platelets (× 109/L)	300.5 ± 56.2	250.2 ± 48.4	239.6 ± 55.6	159.4 ± 69.5
HCV RNA (× 103 IU/mL)	684.3 ± 124.8	860.1 ± 1042	1241.5 ± 1286.7	1501.4 ± 1661.0
Fibroscan	4.70 ± 0.75	6.30 ± 0.36	9.90 ± 1.78	23.27 ± 9.30
Activity
A0-A1	20 (66.7)	13 (43.3)	10 (33.3)	1 (3.3)
A2-A3	10 (33.3)	17 (56.7)	20 (66.7)	29 (96.7)
Steatosis
≤ 33%	28 (93.3)	26 (86.7)	16 (53.3)	4 (13.3)
> 33%	2 (6.7)	4 (13.3)	14 (46.7)	26 (86.7)

The clinical data was compared in HCV patients with different fibrosis grades: F0 (n = 30), F1 (n = 30), F2-F3 (n = 30), F4 (n = 30). The quantitative data were represented as mean ± SD while qualitative data were represented as n (%). HCV: Hepatitis C virus; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate transaminase; ALP: Alkaline phosphatase.